Plant ID: NPO27144
Plant Latin Name: Daiswa dunniana
Taxonomy Genus: Daiswa
Taxonomy Family: Melanthiaceae
NCBI TaxonomyDB:
374961
Plant-of-the-World-Online:
n.a.
TSHR; | |
ACHE; | |
CA12; CA9; | |
NFKB1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.430E-13 | 1.182E-08 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.111E-12 | 3.387E-08 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.789E-11 | 9.739E-08 | CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.899E-09 | 1.052E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.341E-09 | 1.454E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.926E-09 | 1.944E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.193E-08 | 3.979E-05 | CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 6.769E-08 | 1.053E-04 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.853E-08 | 1.069E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 1.589E-04 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.351E-07 | 2.226E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.235E-07 | 6.059E-04 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.447E-06 | 1.086E-03 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 4.119E-06 | 2.718E-03 | CA12, CA9, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.059E-06 | 3.060E-03 | CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.083E-05 | 5.896E-03 | CYP2C19, CYP2C9 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 5.026E-05 | 2.432E-02 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.048E-10 | 7.444E-09 | CYP2C9, CYP2A6, CYP2D6, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.373E-08 | 1.197E-06 | CYP2C9, CYP2A6, CYP2D6, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.409E-08 | 1.280E-06 | CYP2C9, CYP2A6, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.267E-07 | 5.798E-06 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.868E-06 | 5.493E-05 | CYP2C9, CYP2A6, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.994E-05 | 2.359E-04 | CYP2C9, CYP2D6, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.187E-04 | 3.303E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 2.302E-04 | 2.043E-03 | CYP2A6, CYP3A4 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.276E-03 | 1.612E-02 | CYP2C9, CYP2A6, CYP2C19, CYP3A4 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.048E-05 | 3.091E-04 | CA12, CA9 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |